Fulgent Genetics (FLGT) Current Deferred Revenue (2018 - 2026)

Fulgent Genetics (FLGT) has 9 years of Current Deferred Revenue data on file, last reported at $3.0 million in Q1 2026.

• Quarterly Current Deferred Revenue rose 6.74% year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.0 million (up 6.74% YoY) and the FY2025 annual result came in at $3.6 million, up 62.71% from the prior year.
• Current Deferred Revenue eased to $3.0 million in Q1 2026 per FLGT's latest filing, from $3.6 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $14.1 million in Q1 2022, with the low at $2.2 million in Q4 2024.
• Average Current Deferred Revenue over 5 years is $3.9 million, with a median of $2.8 million recorded in 2024.
• Year-over-year, Current Deferred Revenue slumped 80.62% in 2023 and soared 62.71% in 2025.
• Fulgent Genetics' Current Deferred Revenue stood at $3.2 million in 2022, then retreated by 10.16% to $2.9 million in 2023, then slipped by 22.27% to $2.2 million in 2024, then soared by 62.71% to $3.6 million in 2025, then declined by 17.28% to $3.0 million in 2026.
• Business Quant data shows FLGT's Current Deferred Revenue at $3.0 million in Q1 2026, $3.6 million in Q4 2025, and $2.3 million in Q3 2025.